SCHEMBL17466945

SCHEMBL17466945

CCOC(=O)c1cnc(C)nc1NC1(C)C(C)(C)C(C)(C)C(C)(C)C1(C)C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOS P01100 4/20 0.53
JUN P05412 4/20 0.53
NFKB1 P19838 4/20 0.53
NFKB2 Q00653 4/20 0.53
RELA Q04206 4/20 0.53
KDM4E B2RXH2 4/20 0.45
ALDH1A1 P00352 3/20 0.45
MAPT P10636 2/20 0.45
NPC1 O15118 1/20 0.45
HPGD P15428 1/20 0.45
HSD17B10 Q99714 1/20 0.45
AGTR1 P30556 1/20 0.42
AGTR2 P50052 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CSNK1D P48730 1/20 0.41
SYK P43405 1/20 0.41
HSP90AA1 P07900 1/20 0.41
NPSR1 Q6W5P4 4/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15624862 0.80 ALDH1A1 (0.60) FOSJUNNFKB1NFKB2RELA
SCHEMBL19320623 0.79 FOS (0.58) FOSJUNNFKB1NFKB2RELA
SCHEMBL10400985 0.78 FOS (0.60) FOSJUNNFKB1NFKB2RELA
SCHEMBL1627061 0.74 FOS (0.53) FOSJUNNFKB1NFKB2RELA
SCHEMBL1669574 0.74 RAB9A (0.56) FOSJUNNFKB1NFKB2RELA
SCHEMBL30996914 0.74 RAB9A (0.56) FOSJUNNFKB1NFKB2RELA
SCHEMBL959574 0.72 CSNK1D (0.54) FOSJUNNFKB1NFKB2RELA
SCHEMBL9496451 0.72 ALDH1A1 (0.51) FOSJUNNFKB1NFKB2RELA
SCHEMBL6604256 0.71 SMN1; SMN2 (0.63) NFKB1NFKB2RELAKDM4EALDH1A1
SCHEMBL427402 0.71 ALDH1A1 (0.63) FOSJUNNFKB1NFKB2RELA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180051022-A1 DEUTERATED PALBOCICLIB CONCERT PHARMACEUTICALS, INC. 2018-02-22 US disclosed
US-20160024084-A1 DEUTERATED PALBOCICLIB CONCERT PHARMACEUTICALS, INC. 2016-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024084-A1 DEUTERATED PALBOCICLIB CDK4, CDK6, CDK3 FOS 2180/4885JUN 1229/4885NFKB1 1168/4885
US-20180051022-A1 DEUTERATED PALBOCICLIB CDK4, CDK6, CDK3 FOS 1957/4885JUN 1512/4885NFKB1 963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.